Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma

Journal of Clinical Oncology

Volumn 20, Issue 10, 2002, Pages 2472-2479

  Gisselbrecht, Christian ^a   Lepage, Eric ^a   Molina, Thierry ^a   Quesnel, Bruno ^a   Fillet, Georges ^a   Lederlin, Pierre ^a   Coiffier, Bertrand ^a   Tilly, Hervé ^a   Gabarre, Jean ^a   Guilmin, Francoise ^a   Hermine, Olivier ^a   Reyes, Félix ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; VINDESINE;

ADULT; AGE; ARTICLE; AUTOTRANSPLANTATION; BLOOD TOXICITY; BONE MARROW METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG RESPONSE; EVALUATION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INFECTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; REMISSION; RISK FACTOR; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BLOOD CELLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINDESINE;

EID: 0037093068     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.02.125     Document Type: Article

References (37)

1. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
2. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
3. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem-Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the jury
4. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma
5. High-dose chemotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: A pilot study
6. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and highgrade B-cell non-Hodgkin's lymphoma in first remission: A pilot study
7. Autologous bone marrow transplantation for non-Hodgkin's lymphoma in first remission
8. Survival benefit from high-dose therapy with autologous blood progenitor cell transplantation in poor-prognosis non-Hodgkin's lymphoma
9. Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI)
10. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high risk diffuse large-cell lymphoma
11. Survival benefit of high dose therapy in poor risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol-A Groupe d'Etude des Lymphomes de 1'Adulte study
12. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group
13. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
14. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma
15. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma
16. LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma
17. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: The LNH87- 1 study
18. A randomized comparison of ACVBP and CHOP in the treatment of advanced aggressive non-Hodgkin's lymphoma: The LNH93-5 study
19. Intensified phase including autologous peripheral stem cell transplantation does not improve response rate and survival in lymphoma with at least 2 adverse prognostic factors when compared to ACVB regimen
20. Updated Kiel classification for lymphomas
21. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
22. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas
23. Factors affecting hematopoietic recovery after autologous peripheral blood progenitorcell transplantation in aggressive non-Hodgkin's lymphoma: A prospective study of 123 patients
24. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma
25. Non parametric estimation from incomplete observations
26. Evaluation of survival data and two new rank order statistics arising in its consideration
27. Hazard function estimators: A simulation study
28. Regression models and life tables
29. Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity
30. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: One-half of patients significantly mobilize malignant cells
31. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission
32. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor risk aggressive non Hodgkin's lymphoma: Updated results of the prospective study LNH87-2
33. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to the LNH- 87 protocol
34. Placebo controlled phase III trial of lenograstim (glycosylated recombinant human G-CSF) in aggressive non-Hodgkin's lymphoma
35. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study
36. High dose therapy with autologous stem cell transplantation in aggressive NHL: Results of a randomized multicenter study
37. CHOP plus rituximab with CHOP chemotherapy in elderly patients with diffuse large B-cell lymphoma: A Groupe d'Etude des Lymphomes de l'Adulte study